Exhaled nitric oxide is reduced in infants with cystic fibrosis

H E Elphick1, E A Demoncheaux, S Ritson

  • 1Pediatric Respiratory Unit, Sheffield Children's Hospital, Sheffield S10 2TH, UK.

Thorax
|February 24, 2001
PubMed

Insights

Infants with cystic fibrosis (CF) show lower exhaled nitric oxide levels before symptoms appear. This finding offers insights into early CF inflammation and potential new treatments.

Area of Science:

  • Pulmonary Medicine
  • Pediatric Respiratory Research
  • Biomarker Discovery

Background:

  • Cystic Fibrosis (CF) is characterized by airway inflammation, yet exhaled nitric oxide (eNO) levels are paradoxically low.
  • Investigating eNO in early CF may reveal underlying inflammatory mechanisms.
  • Understanding early inflammatory processes is crucial for timely intervention.

Purpose of the Study:

  • To determine if exhaled nitric oxide levels are reduced in infants with CF before respiratory symptoms manifest.
  • To investigate the role of eNO as a potential early biomarker for CF.

Main Methods:

  • Exhaled nitric oxide was measured using a chemiluminescence analyzer.
  • Study included five infants diagnosed with CF and 11 healthy control infants.
  • Participants were of similar mean age (48.6 days).

Main Results:

  • Infants with CF exhibited significantly lower mean exhaled nitric oxide levels (4.9 ppb) compared to healthy controls (12.1 ppb).
  • The difference in eNO levels was statistically significant (p=0.01).

Conclusions:

  • Reduced eNO levels in infants with CF suggest an early inflammatory pathway distinct from typical inflammatory responses.
  • This finding could be pivotal in understanding early-stage cystic fibrosis.
  • Further research may lead to novel therapeutic strategies targeting these early inflammatory processes.
Abstract

Related Concept Videos

Breathing01:05

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...